Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 10/20 | 0.52 |
| ▸ | TNNI3K | Q59H18 | 10/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124294 | 0.91 | KDR (0.52) | RAF1KDRTNNI3KMAPK14BRAF | |
| SCHEMBL5198659 | 0.89 | KDR (0.51) | TP53RAF1KDRTNNI3KMAPK14 | |
| SCHEMBL4111952 | 0.81 | TP53 (0.73) | TP53KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4119219 | 0.80 | KDM4E (0.77) | KDM4EALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4104721 | 0.79 | KDR (0.55) | TP53RAF1KDRTNNI3KMAPK14 | |
| SCHEMBL4119179 | 0.79 | SMN1; SMN2 (0.73) | TP53KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4118526 | 0.77 | MAPT (0.66) | KDM4EALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4110649 | 0.77 | MAPT (0.74) | TP53KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4116166 | 0.76 | MAPT (0.58) | KDM4EALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4105198 | 0.75 | MAPT (0.68) | KDM4EALDH1A1MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | TP53 4802/4885RAF1 2587/4885KDR 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.